MINIPRESS

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Estonia, Japan, Lithuania, Spain.

Active ingredients

The drug MINIPRESS contains one active pharmaceutical ingredient (API):

1	Prazosin UNII X0Z7454B90 - PRAZOSIN HYDROCHLORIDE
	Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease.
	Read more about Prazosin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MINIPRESS Capsule	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02CA01	Prazosin	C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1478T, 1479W, 1480X
BR	Câmara de Regulação do Mercado de Medicamentos	522717120068207, 522717120068307, 522717120068407
EE	Ravimiamet	1022768, 1136607, 1172517, 1782312, 1782389, 1789702, 1799174, 1816635
ES	Centro de información online de medicamentos de la AEMPS	55062, 55063, 55064
JP	医薬品医療機器総合機構	2149002F1128, 2149002F2159
LT	Valstybinė vaistų kontrolės tarnyba	1090658
US	FDA, National Drug Code	0069-4310, 0069-4370, 0069-4380